All In Biotech

Drug Trial Radar · NCT05183178

Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome

Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome-a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 17,095 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

17,095

Actual

Start

Feb 1, 2022

Primary completion

Aug 31, 2025

Study completion Aug 31, 2025

Sponsor

Lead sponsor
Vastra Gotaland RegionGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Region Skane; Region Halland; Region Gävleborg; Region Örebro County; Region Västerbotten; Jämtland County Council, Sweden
First posted
Jan 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study proposes to conduct the switch from ticagrelor to prasugrel in an organized stepwise manner, to allow for the evaluation of the relative efficacy of prasugrel versus ticagrelor using a stepped-wedge cluster randomized trial design.

Conditions

  • Acute Coronary Syndrome

Interventions

  • Prasugrel 10 mg p.oDrug

    Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.

  • Ticagrelor 90 mgDrug

    Ticagrelor 90 mg twice daily p.o.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative risk (%)Time frame: 1-year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dep. Cardiology, Skånes universitetssjukhus

    Lund, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.